Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy
/in International Publications, Newcastle Disease Virus /von 2017-05-23 / Cancer Res. 2017 08;77(15):4146-4157Immunobiology of Newcastle Disease Virus and Its Use for Prophylactic Vaccination in Poultry and as Adjuvant for Therapeutic Vaccination in Cancer Patients
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2017-05-20 / Int J Mol Sci 2017 May;18(5)Enhanced DNA Damages of Human Prostate Cancer Cells Induced by Radiofrequency Capacitive Hyperthermia Pre- and Post X-rays: 6 MV versus 15 MV
/in Hyperthermia, International Publications, Pancreatic Cancer /von 2017-05-17 / Cell J 2017;19(Suppl 1):79-85The Role of Radiofrequency Hyperthermia in The Radiosensitization of A Human Prostate Cancer Cell Line
/in Hyperthermia, International Publications, Pancreatic Cancer /von 2017-05-17 / Cell J 2017;19(Suppl 1):86-95Immunotherapeutic approaches for hepatocellular carcinoma
/in Dendritic Cells, Hepatocellular Carcinoma, International Publications /von 2017-05-16 / Oncotarget 2017 05;8(20):33897-33910Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives
/in International Publications, Newcastle Disease Virus /von 2017-05-15 / Front Immunol 2017;8:555A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients
/in Dendritic Cells, Glioblastoma, International Publications /von 2017-05-12 / J Transl Med 2017 05;15(1):104Vaccine-based immunotherapeutic approaches to gliomas and beyond
/in Dendritic Cells, Glioblastoma, International Publications /von 2017-05-12 / Nat Rev Neurol 2017 Jun;13(6):363-374Trial watch: Dendritic cell-based anticancer immunotherapy
/in Dendritic Cells, International Publications /von 2017-05-12 / Oncoimmunology 2017;6(7):e1328341
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution